| 0.65 -0.014 (-2.15%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.07 | 1-year : | 1.27 |
| Resists | First : | 0.92 | Second : | 1.09 |
| Pivot price | 0.71 |
|||
| Supports | First : | 0.64 | Second : | 0.53 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.74 |
| MA(100) : | 1.03 |
MA(250) : | 1.12 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.7 |
D(3) : | 6.6 |
| RSI | RSI(14): 24.4 |
|||
| 52-week | High : | 1.44 | Low : | 0.64 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ENZ ] has closed below the lower bollinger band by 4.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.69 | 0.69 - 0.69 |
| Low: | 0.64 - 0.64 | 0.64 - 0.65 |
| Close: | 0.64 - 0.65 | 0.65 - 0.66 |
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Tue, 14 Jan 2025
Enzo Biochem Receives NYSE Non-Compliance Notice Over Market Cap and Share Price Issues - StockTitan
Tue, 14 Jan 2025
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges - MSN
Fri, 20 Dec 2024
Enzo Biochem (ENZ) Stock Surges 5.19% Amid Market Activity - GuruFocus.com
Wed, 18 Dec 2024
Enzo Biochem, Inc.'s (NYSE:ENZ) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St
Mon, 16 Dec 2024
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update - GlobeNewswire
Mon, 16 Dec 2024
Enzo Biochem Reports 20% Revenue Drop Amid Life Sciences Slowdown; Maintains $47.7M Cash Position - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 52 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 21.5 (%) |
| Held by Institutions | 31.7 (%) |
| Shares Short | 422 (K) |
| Shares Short P.Month | 477 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | -81.8 % |
| Operating Margin | -38.8 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -14.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.61 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -4.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 1.06 |
| Price to Cash Flow | -1.3 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 15.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|